Is there an impact of killer cell immunoglobulin-like receptors and KIR-ligand incompatibilities on outcomes after unrelated cord blood stem cell transplantation?

Best Practice and Research: Clinical Haematology

Volumn 23, Issue 2, 2010, Pages 283-290

  Willemze, Roel ^a   Ruggeri, Annalisa ^a   Purtill, Duncan ^a   Rodrigues, Celso Arrais ^a   Gluckman, Eliane ^a   Rocha, Vanderson ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

KIR; KIR ligand incompatibility; umbilical cord blood transplantation

Indexed keywords

CD16 ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; CD94 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A ANTIGEN; HLA A11 ANTIGEN; HLA A3 ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DR ANTIGEN; HLA G ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; PROTEIN TYROSINE PHOSPHATASE SHP 1; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOLYSIS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DONOR; ENGRAFTMENT; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; LEUKEMIA RELAPSE; LYMPHATIC LEUKEMIA; LYMPHOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; MORTALITY; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; RELAPSE; REVIEW; TREATMENT OUTCOME;

CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE-FREE SURVIVAL; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; INCIDENCE; LEUKEMIA; LIGANDS; RECEPTORS, KIR; SURVIVAL RATE; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 77956563350     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2010.05.005     Document Type: Review

References (46)

1. J.H.F. Falkenburg, W.A.F. Marijt, and M.H. Heemskerk Minor histocompatibility antigens as target of graft-versus-leukemia reactions Curr Opin Hematol 9 2002 497 502
2. H.J. Kolb, A. Schattenberg, and J.M. Goldman Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients Blood 86 1995 2041 2050
3. S.S. Farag, T.A. Fehninger, and L. Ruggeri Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect Blood 100 2002 1935 1947
4. L. Moretta, and A. Moretta Killer immunoglobulin-like receptors Curr Opin Immunol 16 2004 626 633
5. P. Parham MHC class I molecules and KIRs in human history, health and survival Nat Rev Immunol 5 2005 201 214
6. L.L. Lanier NK cell recognition Annu Rev Immunol 23 2005 225 274
7. M.B. Lodoen, and L.L. Lanier Natural killer cells as an initial defense against pathogens Curr Opin Immunol 18 4 2006 Aug 391 398
8. G. Trinchieri Biology of natural killer cells Adv Immunol 47 1989 187 376
9. C.A. Biron, K.B. Nguyen, and G.C. Pien Natural killer cells in antiviral defense: function and regulation by innate cytokines Annu Rev Immunol 17 1999 189 220
10. C. Fauriat, E.O. Long, and H.G. Ljunggren Regulation of human NK-cell cytokine and chemokine production by target cell recognition Blood 115 11 2010 Mar 18 2167 2176
11. H.G. Ljunggren, and K. Karre In search of the "missing self": MHC molecules and NK cell recognition Immunol Today 11 1990 237 244
12. F.M. Karlhofer, R.K. Ribaudo, and W.M. Yokoyama MHC class I alloantigen specificity of Ly-49+IL-2-activated natural killer cells Nature 358 1992 66 70
13. E. Vivier, and N. Anfossi Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future Nat Rev Immunol 4 2004 190 198
14. C.A. Biron, and L. Brossay NK cells and NKT cells in innate defense against viral infections Curr Opin Immunol 13 2001 458 464
15. M.A. Caligiuri Human natural killer cells Blood 112 2008 461 469
16. S.G. Marsh, P. Parham, and B. Dupont Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002 Tissue Antigens 62 2003 79 86 (Pubitemid 36918680)
17. R. Biassoni, C. Cantoni, and M. Falco The human leukocyte antigen (HLA)-C-specific "activatory" or "inhibitory" natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions J Exp Med 183 2 1996 645 650
18. B.A. Foley, D. De Santis, and E. Van Beelen The reactivity of Bw4+ HLA-B and HLA-A alleles with KIR3DL1: implications for patient and donor suitability for haploidentical stem cell transplantation Blood 112 2008 435 443
19. M. Stern, L. Ruggeri, and M. Capanni Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1 Blood 112 2008 708 710
20. P. Hansasuta, T. Dong, and H. Thananchai Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific Eur J Immunol 34 2004 1673 1679
21. D. Middleton, and F. Gonzelez The extensive polymorphism of KIR genes Immunology 129 2009 8 19
22. W. Leung, R. Iyengar, and B. Triplett Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors J Immunol 174 2005 6540 6545
23. W. Leung, R. Iyengar, and V. Turner Determinants of antileukemia effects of allogeneic NK cells J Immunol 172 2004 644 650
24. L. Ruggeri, A. Mancusi, and M. Capanni Donor natural killer cell allorecognition of missing self in haploidentical hematopoieitc transplantation for acute myeloid leukemia: challenging its predictive value Blood 110 2007 433 440
25. L. Ruggeri, M. Capanni, and M. Casucci Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation Blood 94 1999 333 339
26. L. Ruggeri, M. Capanni, and E. Urbani Effectiveness of donor natural killer alloreactivity in mismatched haematopoietic transplants Science 295 2002 2097 2100
27. J.S. Miller, S. Cooley, and P. Parham Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT Blood 109 2007 5058 5061
28. S. Giebel, F. Locatelli, and T. Lamparelli Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors Blood 102 2003 814 819
29. D.W. Beelen, H.D. Ottinger, and S. Ferencik Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias Blood 105 2005 2594 2600
30. K. Hsu, C.A. Keever-Taylor, and A. Wilton Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes Blood 105 2005 4878 4884
31. S.M. Davies, L. Ruggieri, and T. DeFor Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants Blood 100 2002 3825 3827
32. S.S. Farag, A. Bacigalupo, and M. Eapen The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the Center for International Blood and Bone Marrow Transplant Research, the European Blood and Bone Marrow Transplant Registry, and the Dutch registry Biol Blood Marrow Transplant 12 2006 876 884
33. M. Bornhauser, R. Schwerdtfeger, and H. Marin Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors Blood 103 2004 2860 2861
34. M.A. Cook, D.W. Milligan, and C.D. Fegan The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia Blood 103 2004 1521 1526
35. J.Y. Sun, A. Dagis, and L. Gaidulis Detrimental effect of natual killer cell alloreactivity in T-replete hematopoietic stem cell transplantation for leukaemia patients Biol Blood Marrow Transplant 13 2007 197 205
36. A.J. Schellekens, E.H. Rozemuller, and E.J. Petersen Activating KIRs exert a crucial role on relapse and overall survival after HLA-identical sibling transplantation Mol Immunol 45 2008 2255 2261
37. C. Chen, M. Busson, and V. Rocha Activating KIR genes are associated with CMV reactivation and survival after non-T cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders Bone Marrow Transplant 38 2006 437 444
38. E.J. Lowe, V. Turner, and R. Handgretinger T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation Brit J Haematol 123 2003 323 326
39. E. Gluckman, and V. Rocha History of the clinical use of umbilical cord blood hematopoietic cells Cytotherapy 7 2005 219 227
40. E. Gluckman, and V. Rocha Donor selection for unrelated cord blood transplants Curr Opin Immunol 18 2006 565 570
41. V. Rocha, J. Cornish, and E.L. Sievers Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia Blood 97 10 2001 2962 2971
42. V. Rocha, M. Labopin, and G. Sanz Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia N Engl J Med 351 2004 2276 2285
43. M. Eapen, P. Rubinstein, and M.J. Zhang Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study Lancet 369 2007 1947 1954
44. C.G. Brunstein, J.E. Wagner, and D.J. Weisdorf Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity Blood 113 2009 5628 5634
45. R. Willemze, C.A. Rodrigues, M. Labopin Eurocord-Netcord and Acute Leukaemia Working Party of the EBMT KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia Leukemia 23 2009 492 500
46. A. Ruggeri, D. Purtill, and G. Michel Outcomes of unrelated cord blood transplantation for non-malignant diseases in children are not associated with KIR-ligand matching between donor and recipient: a study on behalf of Eurocord Blood 114 Nov 2009 2301